Navigation Links
China Sky One Medical's Subsidiaries Recognized as Provincial Model Companies
Date:6/2/2010

HARBIN, China, June 2 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced that its wholly owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, Heilongjiang Tianlong Pharmaceutical, Inc. and Heilongjiang Haina Pharmaceutical, Inc. have been recognized as Heilongjiang's Model Companies by the Heilongjiang Provincial Government.

Each year, the Heilongjiang Provincial Government will select 200 to 300 Model Companies from over 20,000 companies in Heilongjiang Province. These Model Companies are viewed as leaders in their respective industries and have established a track record in demonstrating responsibility to their employees, customers and the overall public.

"We are honored that our operating subsidiaries have been designated as Model Companies and look forward to continue to provide leadership in the pharmaceutical industry throughout Heilongjiang Province," said Mr. Yanqing Liu, China Sky One Medical's Chief Executive Officer. "As recognized by these designations, China Sky One Medical has been and remains committed to serving our customers, providing good working environment for our employees and positively contributing to the society. We believe that building and maintaining a high quality brand and strong corporate image will support the Company's long term growth
'/>"/>

SOURCE China Sky One Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)...  Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company ... technology to deter prescription drug abuse today announced ... Soscia , has been chosen as a ... Health-Care Heroes Awards. The awards are presented annually ... individuals and organizations demonstrating excellence and deserving recognition ...
(Date:5/20/2013)... 2013 Enrollment of patients with Type 2 ... clinical trial of product candidate NewMet ™, a ... Type 2 diabetes. Elcelyx expects to complete enrollment of ... Results of the trial,s primary endpoint of change in ... the read-out for long-term glucose lowering and weight benefits ...
(Date:5/20/2013)... ROCKVILLE, Md. , May 20, 2013  Neuralstem, ... Eva Feldman , MD, PhD, principal investigator, presented ... neural stem cell (NSI-566) trial in the treatment of ... ,s disease) at the neuro diabetes special medical ... Friday. In a talk called "Recent Therapeutic Advances in ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
... , PLEASANTON, Calif., Dec. 2 Roche (SIX: RO, ROG; ... Drug Administration (FDA) approved an additional intended use for its ... comprised of up to 96 individual donations. The test, called ... cobas s 201 system, is a qualitative, in-vitro test ...
... , EAST HANOVER, N.J., Dec. ... late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a ... company,s hematology portfolio in advancing the care of patients. ... Hematology (ASH) Annual Meeting and Exposition, highlight the company,s current ...
Cached Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25
(Date:5/20/2013)... Parker Waichman LLP, a national law ... by defective drugs, has filed a lawsuit on behalf ... of the diabetes drug medication Actos (pioglitazone) caused ... 30, 2013, in the U.S. District Court for the ... is one of thousands of cases pending in the ...
(Date:5/20/2013)... 2013 Leading facial plastic surgeon and ENT ... a “Top Doc” in the field of Otolaryngology in the ... The Palm Beacher magazine, one of Palm Beach County’s leading ... the May/June 2013 issue, including 70 of the very best ... events, things to do, health and fitness, people to watch, ...
(Date:5/20/2013)... Mirena IUD lawsuit claims ... recently established in U.S. District Court, Southern District of ... court records, the litigation’s first Status Conference was held ... leadership positions were discussed. So far, at least ... of New York, all of which allege that the ...
(Date:5/20/2013)... 20, 2013 The Environmental ... feature dozens of continuing education credit opportunities for ... Institute of Architects Continuing Education System (AIA/CES), the ... the Interior Design Continuing Education Council (IDCEC). ... 1, 2013 at the Omni Providence Hotel in ...
(Date:5/20/2013)... 2013 Salt Lake Community College’s Know Greater ... Select 25 winners for 2013. As part of the ... Greater Heroes is a leadership training program that involves SLCC ... how to eat right, be active, and avoid drugs and ... Greater Heroes program each year, and visit more than 30 ...
Breaking Medicine News(10 mins):Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Dr. Schwartz Named “Top Doc” by The Palm Beacher Magazine 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:Environmental Design Research Conference to Feature AIA/CES, LA CES, and IDCEC Continuing Education Credits 2Health News:SLCC Know Greater Heroes Program Named to Select 25 2Health News:SLCC Know Greater Heroes Program Named to Select 25 3
... and binge eating , MONDAY, May 10 (HealthDay News) ... the risk of impulse control disorders, such as problem ... In a new study that included 3,090 patients being ... the United States and Canada, the researchers found that ...
... ... Health Services, Inc. (CV10-2011), asserts that Gentiva, which employs some 30,000 health care workers, treats ... FLSA and refuses to pay these employees for all hours worked. , ... New York, NY (PRWEB) May 10, 2010 -- ...
... . Montreal, May 10, 2010 As fewer people ... among North American youth. A study published in the journal ... Montreal had used waterpipes (also known as shishas or hookahs) in ... due in part to perceptions that they are safer than cigarettes. ...
... Nurse staffing ... newly adopted U.S. Health Care Reform legislation. Current healthcare reform legislation indicates that more ... , ... (PRWEB) May 10, 2010 -- Nurse staffing agency, FlexRN, announces its plans to help agency ...
... treatment even when pulmonary disease looks stable, researchers ... of chronic obstructive pulmonary disease (COPD) leads to increased ... study finds. , British researchers looked at 25,857 COPD ... and 633 ischemic strokes (blockage of blood flow to ...
... from the Georgetown Lombardi Comprehensive Cancer Center at Georgetown ... therapy to "rescue" treatment sensitivity to fulvestrant in estrogen ... on May 15, 2010 as the cover story of ... common second-line therapy for women whose cancer progresses following ...
Cached Medicine News:Health News:Parkinson's Drugs Tied to Compulsive Behaviors 2Health News:Martin & Jones Announces Class Action Lawsuit Against Major Employer, Claims Thousands of Visiting Nurses Illegally Denied Overtime Pay 2Health News:Martin & Jones Announces Class Action Lawsuit Against Major Employer, Claims Thousands of Visiting Nurses Illegally Denied Overtime Pay 3Health News:FlexRN Nurse Staffing Agency Prepares Nurses for Demands of Latest Health Care Reform 2Health News:Researchers discover new way to 'rescue' treatment sensitivity of breast cancer cells 2
... The MEL 80 is a top quality ... the correction of vision defects even safer, ... of this ultramodern work platform are oriented ... and the rapid recovery of vision. Key ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
... Escort Controller can be mounted at the ... table top. The design retains many ... controller, such as the pump drive motor ... pump, and infusion system. Retaining these ...
Medicine Products: